Patent · US Active

Indazole kinase inhibitor and use thereof

US12162876B2 · kind B2 · utility

0Cited by

0References

13Claims

0Family size

Assignee

Tarapeutics Science Inc. · CN

Inventors

Jing Liu · San Diego, US
Qingsong LIU · Daguantang, CN
Xuesong Liu · Hangzhou City, CN
Beilei Wang · Meekrap-oord, CN
Cheng-Yu Chen · Longbeilingcun, CN
Ziping Qi · Meekrap-oord, CN
Wenchao Wang · Beijing, CN
Junjie Wang · Beijing, CN
Zongru JIANG · Daguantang, CN
Wenliang Wang · Daguantang, CN
Shuang QI · Lo Wu, CN
Li-Ting Wang · Meekrap-oord, CN

Key dates

Filing date	Nov 12, 2018
Grant date	Dec 10, 2024
Priority date	—
Expiry date	Dec 15, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein is a kinase inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug of the compound. Further described herein is a pharmaceutical composition containing the kinase inhibitor compound, as well as methods of using the compound to inhibit cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 kinase activity in cells or a subject, and methods for preventing or treating disorders related to cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 activity in a subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.